HomeCompareIPSEY vs PLD

IPSEY vs PLD: Dividend Comparison 2026

IPSEY yields 0.86% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $6.48M in total portfolio value
10 years
IPSEY
IPSEY
● Live price
0.86%
Share price
$46.30
Annual div
$0.40
5Y div CAGR
33.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$2,101.14
Full IPSEY calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — IPSEY vs PLD

📍 PLD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIPSEYPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IPSEY + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IPSEY pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IPSEY
Annual income on $10K today (after 15% tax)
$73.26/yr
After 10yr DRIP, annual income (after tax)
$1,785.97/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, PLD beats the other by $4,466,184.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IPSEY + PLD for your $10,000?

IPSEY: 50%PLD: 50%
100% PLD50/50100% IPSEY
Portfolio after 10yr
$3.27M
Annual income
$2,629,268.66/yr
Blended yield
80.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

IPSEY
Analyst Ratings
2
Buy
1
Hold
1
Sell
Consensus: Buy
Altman Z
14.0
Piotroski
7/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IPSEY buys
0
PLD buys
0
No recent congressional trades found for IPSEY or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIPSEYPLD
Forward yield0.86%3.18%
Annual dividend / share$0.40$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR33.9%74.4%
Portfolio after 10y$28.0K$6.50M
Annual income after 10y$2,101.14$5,256,436.18
Total dividends collected$7.1K$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: IPSEY vs PLD ($10,000, DRIP)

YearIPSEY PortfolioIPSEY Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$10,815$115.41$11,255$555.24$440.00PLD
2$11,729$156.20$13,062$1,018.59$1.3KPLD
3$12,762$211.97$15,903$1,926.67$3.1KPLD
4$13,944$288.63$20,839$3,823.32$6.9KPLD
5$15,314$394.64$30,464$8,166.08$15.2KPLD
6$16,929$542.40$52,054$19,457.30$35.1KPLD
7$18,864$750.31$109,886$54,188.93$91.0KPLD
8$21,231$1,046.28$304,030$186,451.18$282.8KPLD
9$24,191$1,473.60$1,166,125$840,813.32$1.14MPLD
10$27,985$2,101.14$6,504,190$5,256,436.18$6.48MPLD

IPSEY vs PLD: Complete Analysis 2026

IPSEYStock

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

Full IPSEY Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this IPSEY vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IPSEY vs SCHDIPSEY vs JEPIIPSEY vs OIPSEY vs KOIPSEY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.